TARGETED THERAPIES Afatinib-new therapy option for EGFR-mutant lung cancer

被引：82
|
作者：
Yu, Helena A. [1 ]
Pao, William [2 ]
机构：
[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10065 USA
[2] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN 37212 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 10期
关键词：
1ST-LINE TREATMENT; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; PHASE-3; TRIAL;
D O I：
10.1038/nrclinonc.2013.154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.
引用
收藏
页码：551 / 552
页数：2
相关论文
共 50 条
  • [41] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
    Tone, Mari
    Iwahori, Kota
    Shiroyama, Takayuki
    Futami, Shinji
    Naito, Yujiro
    Fukushima, Kiyoharu
    Miyake, Kotaro
    Koyama, Shohei
    Hirata, Haruhiko
    Nagatomo, Izumi
    Wada, Hisashi
    Takeda, Yoshito
    Kumanogoh, Atsushi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [42] Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer
    Qin, Qiong
    Li, Xiaoqing
    Liang, Xingmei
    Zeng, Lili
    Wang, Jing
    Sun, Linlin
    Zhong, Diansheng
    THORACIC CANCER, 2021, 12 (11) : 1708 - 1715
  • [43] Generation and validation of a predictive model for estimating survival among patients with EGFR-mutant non-small cell lung cancer
    Lin, Chien-Yu
    Chou, Yun-Tse
    Su, Po-Lan
    Lin, Chien-Chung
    Chang, John Wen-Cheng
    Huang, Chen-Yang
    Fang, Yueh-Fu
    Chang, Ching-Fu
    Kuo, Chih-Hsi Scott
    Hsu, Ping-Chih
    Yang, Cheng-Ta
    Wu, Chiao-En
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (09): : 4208 - +
  • [44] Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer
    Liu, Xiaoke
    Hong, Lingzhi
    Nilsson, Monique
    Hubert, Shawna Marie
    Wu, Shuhong
    Rinsurongkawong, Waree
    Lewis, Jeffery
    Spelman, Amy
    Roth, Jack
    Swisher, Steven
    He, Yong
    Lee, J. Jack
    Fang, Bingliang
    Heymach, John, V
    Zhang, Jianjun
    Le, Xiuning
    LUNG CANCER, 2020, 149 : 33 - 40
  • [45] Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer Implications for Oncogene-Driven Lung Cancer
    Gavralidis, Alexander
    Gainor, Justin F.
    CANCER JOURNAL, 2020, 26 (06) : 517 - 524
  • [46] Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancer
    Huang, Yu-Chen
    Shen, Shih-Min
    Liu, Chien-Ying
    Pavlidis, Stelios
    Wang, Chih-Liang
    Ko, How-Wen
    Chung, Fu-Tsai
    Lin, Tin-Yu
    Feng, Po-Hao
    Lee, Kang-Yun
    Guo, Yi-Ke
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    THORACIC CANCER, 2018, 9 (12) : 1648 - 1655
  • [47] Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
    Schaufler, Diana
    Ast, David F.
    Tumbrink, Hannah L.
    Abedpour, Nima
    Maas, Lukas
    Schwaebe, Ayla E.
    Spille, Inga
    Lennartz, Stefanie
    Fassunke, Jana
    Aldea, Mihaela
    Besse, Benjamin
    Planchard, David
    Nogova, Lucia
    Michels, Sebastian
    Kobe, Carsten
    Persigehl, Thorsten
    Westphal, Theresa
    Koleczko, Sophia
    Fischer, Rieke
    Weber, Jan-Phillip
    Altmueller, Janine
    Thomas, Roman K.
    Merkelbach-Bruse, Sabine
    Gautschi, Oliver
    Mezquita, Laura
    Buettner, Reinhard
    Wolf, Juergen
    Peifer, Martin
    Braegelmann, Johannes
    Scheffler, Matthias
    Sos, Martin L.
    NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [48] Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
    Tricker, Erin M.
    Xu, Chunxiao
    Uddin, Sharmeen
    Capelletti, Marzia
    Ercan, Dalia
    Ogino, Atsuko
    Pratilas, Christine A.
    Rosen, Neal
    Gray, Nathanael S.
    Wong, Kwok-Kin
    Jaenne, Pasi A.
    CANCER DISCOVERY, 2015, 5 (09) : 960 - 971
  • [49] Targeted therapy for lung cancer: Beyond EGFR and ALK
    Herrera-Juarez, Mercedes
    Serrano-Gomez, Cristina
    Bote-de-Cabo, Helena
    Paz-Ares, Luis
    CANCER, 2023, 129 (12) : 1803 - 1820
  • [50] Adjuvant TKI treatment of EGFR-mutant lung cancer-already ripe for decision?
    Kauffmann-Guerrero, Diego
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 964 - 966
12345